MétaCan
Menu
← Back to cohort
Record W4361825791 · doi:10.1158/0008-5472.c.6514337

Data from Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma

2023· preprint· en· W4361825791 on OpenAlexaff
Anna Borgenvik, Karl O. Holmberg, Sara Bolin, Miao Zhao, Vasil Savov, Gabriela Rosén, Sonja Hutter, Alexandra Garancher, Aldwin Suryo Rahmanto, Tobias Bergström, Thale Kristin Olsen, Oliver J. Mainwaring, Damiana Sattanino, Annemieke D. Verbaan, Jessica M. Rusert, Anders Sundström, Mar Ballester Bravo, Yonglong Dang, Amelie S. Wenz, Stacey Richardson, Grammatiki Fotaki, Rebecca M. Hill, Adrian M. Dubuc, Antonia Kalushkova, Marc Remke, Matko Čančer, Helena Jernberg‐Wiklund, G Giraud, Xingqi Chen, Michael D. Taylor, Olle Sangfelt, Steven C. Clifford, Ulrich Schüller, Robert J. Wechsler‐Reya, Holger Weishaupt, Fredrik J. Swartling

Bibliographic record

Venuenot available
Typepreprint
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsSickKids FoundationHospital for Sick Children
FundersUppsala Multidisciplinary Center for Advanced Computational ScienceUniversity of California, San FranciscoScience for Life LaboratoryUppsala UniversitetVetenskapsrådetSvenska LäkaresällskapetKnut och Alice Wallenbergs StiftelseCancerfonden
KeywordsMedulloblastomaCancer researchBiologyStem cellTargeted therapyMedicineMesenchymal stem cellInternal medicinePathologyCancerCell biology

Abstract

fetched live from OpenAlex

Abstract Relapse is the leading cause of death in patients with medulloblastoma, the most common malignant pediatric brain tumor. A better understanding of the mechanisms underlying recurrence could lead to more effective therapies for targeting tumor relapses. Here, we observed that SOX9, a transcription factor and stem cell/glial fate marker, is limited to rare, quiescent cells in high-risk medulloblastoma with MYC amplification. In paired primary-recurrent patient samples, SOX9-positive cells accumulated in medulloblastoma relapses. SOX9 expression anti-correlated with MYC expression in murine and human medulloblastoma cells. However, SOX9-positive cells were plastic and could give rise to a MYC high state. To follow relapse at the single-cell level, an inducible dual Tet model of medulloblastoma was developed, in which MYC expression was redirected in vivo from treatment-sensitive bulk cells to dormant SOX9-positive cells using doxycycline treatment. SOX9 was essential for relapse initiation and depended on suppression of MYC activity to promote therapy resistance, epithelial–mesenchymal transition, and immune escape. p53 and DNA repair pathways were downregulated in recurrent tumors, whereas MGMT was upregulated. Recurrent tumor cells were found to be sensitive to treatment with an MGMT inhibitor and doxorubicin. These findings suggest that recurrence-specific targeting coupled with DNA repair inhibition comprises a potential therapeutic strategy in patients affected by medulloblastoma relapse. Significance: SOX9 facilitates therapy escape and recurrence in medulloblastoma via temporal inhibition of MYC/MYCN genes, revealing a strategy to specifically target SOX9-positive cells to prevent tumor relapse.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Dataset · Consensus signal: none
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.127
GPT teacher head0.331
Teacher spread0.204 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreDataset

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same topicGlioma Diagnosis and Treatment→French-language works237,207→